Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dashi Pharmaceutical
Guangzhou, Guangdong, Chinadashipharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Dashi Pharmaceutical is a clinical-stage biopharmaceutical company based in China, focused on the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company's lead candidate, DS-200, is a novel androgen receptor antagonist currently being evaluated in Phase 2 clinical trials for the treatment of metastatic castration-resistant prostate cancer. Dashi Pharmaceutical leverages its expertise in medicinal chemistry to develop high-potency compounds with improved safety profiles compared to existing standards of care. The company aims to address significant unmet medical needs in the Chinese and global markets through targeted drug design.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Dashi Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dashi Pharmaceutical.